SPRO
Spero Therapeutics, Inc.
$2.19
-0.01 (-0.45%)
At close · Jul 6
Market Cap
$126.80M
Shares
57,901,493
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.19
Open$2.17
Day$2.15–2.21
52W$1.80–3.22
Avg vol 30d1.5M
Short int1.8M · 3.2% float · 2.3d
Short vol23%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−9% below
−
Price vs 50-day avg
−15% below
◦
RSI (14)
41 · neutral
−
MACD trend
negative
◦
52-week position
27% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $3 › 200d $2 — 50d above 200d
−
Institutional flow
-11% holders QoQ · +8 funds added
−
Insider flow
Net -$63.4K over 90 days · 100% sells
−
Short interest
3.16% of float · ▲ +7.3% MoM · 2.3 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
50 holders — mid 3-yr range
Fundamentals
Strong
+
Revenue growth
+39% Y/Y
+
EPS growth
+112% Y/Y
−
Free cash flow
$-12.8M
◦
Valuation
P/E 8.1 · in line
+
Balance sheet
net cash $40.3M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−9% below
Bearish
Price vs 50-day avg
−15% below
Bearish
RSI (14)
41 · neutral
Neutral
MACD trend
negative
Bearish
52-week position
27% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Distributing
-11% holders QoQ · +8 funds added
Insider flow
Distributing
Net -$63.4K over 90 days · 100% sells
Short interest
Rising
3.16% of float · ▲ +7.3% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
50 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $2 · 27%
52-wk high $3
vs 200-day avg -9%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRO
this stock
Spero Therapeutics, Inc.
|
$126.80M | -6.0% | -53.8% | 8.1 | 3.2% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.92B | +16.8% | +46.2% | 31.1 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRO | -3.1% | -26.5% | -14.1% | -0.9% | -6.0% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | -6.2% | -25.7% | -22.4% | -1.5% | -16.2% |